Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplemental Figure 1 a b c d.

Published byEunice Cummings Modified over 5 years ago

Similar presentations

Presentation on theme: "Supplemental Figure 1 a b c d."— Presentation transcript:

1 Supplemental Figure 1 a b c d

2 Supplemental Figure 2 a b c

3 Supplemental Figure 2 d IB: SUSD3 IB: b-actin siCTL siSUSD3

4 Supplemental Figure 3 a b Control Control + UV Oligo 4 Oligo 5 MCF7
T47D

5 Supplemental Figure 4 a b siCTL siSUSD3 siCTL siSUSD3 oligo 5
Phase (48 hr) IB: SUSD3 IB: b-actin b Phallodin Paxillin Phalloidin + Paxillin siCTL 10 mm 10 mm 10 mm siSUSD3 oligo 5 10 mm 10 mm 10 mm

6 Supplemental Figure4 c GFP-only MCF7 cells Phallodin GFP Merge siCTL
siSUSD3 SUSD3-GFP MCF7 cells Phallodin GFP Merge siCTL siSUSD3

7 Supplemental Figure 5 a b c IB: SUSD3 IB: β-actin IB: SUSD3
siSUSD3 oligo 5 siCTL IB: SUSD3 IB: β-actin b c siSUSD3 oligo 5 siCTL IB: SUSD3 IB: β-actin

Download ppt "Supplemental Figure 1 a b c d."

Similar presentations

a b c Supplementary Figure S1

a b c Supplementary Figure S1
Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
Duong et al Figure 1 A InputsGST-Mdm2 HEGO HE11HE19HE15 HEGO HE11 HE19HE15 B HEGO A/BCEFD 1595 HE11 A/BEFD CEFD HE19 A/BC HE15 C D ER  I GST-Mdm2GST C.

Duong et al Figure 1 A InputsGST-Mdm2 HEGO HE11HE19HE15 HEGO HE11 HE19HE15 B HEGO A/BCEFD 1595 HE11 A/BEFD CEFD HE19 A/BC HE15 C D ER  I GST-Mdm2GST C.
P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
Phase Difference = 0.00. Phase Difference = 0.05.

Phase Difference = Phase Difference = 0.05.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
In what phase is cell #1?. Name this part of the microscope.

In what phase is cell #1?. Name this part of the microscope.
ER  HSP90 DMSO 200  M I3C30  M DIM200  M TRYPTOPHOL Supplemental Figure 1. DIM and Tryptophol fail to induce the downregulation of ER  seen with I3C.

ER  HSP90 DMSO 200  M I3C30  M DIM200  M TRYPTOPHOL Supplemental Figure 1. DIM and Tryptophol fail to induce the downregulation of ER  seen with I3C.
PatientVPA final dose (mg/kg/day) VPA final serum level (mM)(mg/L) 1500.62990.7 2451.081156.0 3200.57382.6 4700.765110.4 5200.61789.0 6300.54278 Supplemental.

PatientVPA final dose (mg/kg/day) VPA final serum level (mM)(mg/L) Supplemental.
Supplemental Figure 1: ER  expression in MCF-7 cells. MCF-7 cells were either pre-treated with ICI 182,780 (lanes 5-8) or EtOH (vehicle, lanes 1-4) for.

Supplemental Figure 1: ER  expression in MCF-7 cells. MCF-7 cells were either pre-treated with ICI 182,780 (lanes 5-8) or EtOH (vehicle, lanes 1-4) for.
0 4 8 12 24 48 (hr) Cleaved Caspase-9 Caspase-8 100 nM Paclitaxel MCF-7 Figure S1a.

(hr) Cleaved Caspase-9 Caspase nM Paclitaxel MCF-7 Figure S1a.
Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%
B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.

B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.
Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.
The reading is 7.38 mm. The reading is 7.72 mm.

The reading is 7.38 mm. The reading is 7.72 mm.
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
From: Activation of the Rho/Rho Kinase Signaling Pathway Is Involved in Cell Death of Corneal Endothelium Invest. Ophthalmol. Vis. Sci.. 2016;57(15):6843-6851.

From: Activation of the Rho/Rho Kinase Signaling Pathway Is Involved in Cell Death of Corneal Endothelium Invest. Ophthalmol. Vis. Sci ;57(15):
Progesterone receptor

Progesterone receptor
Supplementary Figure S1.

Supplementary Figure S1.

Similar presentations

Ads by Google